Holen Sie sich die Stockscreener-App
0.957
3.30%
0.0306
Handel nachbörslich:
.95
-0.007
-0.73%
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Ocugen to Release New Investor Presentation - TipRanks
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN
OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga
Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener
Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus
FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN
Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus
Ocugen To Present at BIO International Convention 2025 - Ocugen
Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus
Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq
Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World
Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Signs License Agreement for OCU400 in Korea - TipRanks
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com
Ocugen, Inc. Announces Signing of Binding Term Sheet for the Lic - GuruFocus
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus
Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire
Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph
OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - Revista ADVFN
Ocugen, Inc. (NASDAQ:OCGN) Stock Position Raised by ProShare Advisors LLC - Defense World
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN
FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -
Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN
FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals
Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com
Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus
FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com South Africa
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):